Biotech firm Evotec enters Schuldschein market
stadtratte - stock.adobe.com
Evotec, the biotech and healthcare company headquartered in Hamburg, has launched a Schuldschein with a €100m starting target.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts